MannKind Shares Data Backing Furoscix ReadyFlow for Outpatient Fluid Overload

MannKind announced new analyses of Furoscix ReadyFlow showing comparable urine output to intravenous furosemide for outpatient fluid overload. A randomized crossover study found equivalent total drug exposure at thigh and upper-arm injection sites, with relative bioavailability of 91.3% and 92.7%. The findings were scheduled for presentation at HFSA 2026, and ReadyFlow received FDA approval in July 2026.
Also covered by: BiopharmaWatch
This summary is Al-enhanced to contain extended analysis and broader social context. The original is {NAME); the linked article is the authoritative source. Original headline: “MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD) | MNKD Stock News.” Browse more stories.